Partnership Opportunity RareCyte already engages with research institutions and biopharma via spatial proteomics and liquid biopsy platforms, presenting a prime opening for strategic collaborations, co-development, and contract research services to expand their market reach.

Expansion Momentum The April 2026 launch of Orion HT and Orion LE systems signals rapid product expansion and new capability tiers, creating opportunities for upsell to current customers and cross-sell to adjacent labs seeking larger-scale spatial biology solutions.

Funding Signals Recent Gates Foundation support underscores validated impact in translational research; leverage this funding momentum to propose targeted grant-driven initiatives, pilot projects, and sponsored research programs with potential funders.

Strategic Alliances Existing collaborations with Navigate Biopharma and academic partners indicate openness to ecosystem partnerships; target additional distributors, CROs, and tumor atlas initiatives to broaden distribution and service coverage.

Global Growth With a mid-size employee base and substantial revenue funnel, focus on expanding customer success, training, and local support to accelerate adoption in new regions while highlighting total cost of ownership and ROI for lab leadership.